Jazz Pharma climbs after Morgan Stanley raises PT

Jazz Pharmaceuticals

07/03/2025 14:43

** Jazz Pharmaceuticals' JAZZ.O shares rise 3% to $141.29

** Brokerage Morgan Stanley raises PT to $183 from $175, a 34.1% upside to the stock's last close; maintains "overweight" rating

** Says growth of Jazz's newer sleep disorder drug Xywav in H1 should offset ongoing switch from older drug Xyrem

** Sees 'meaningful expansion' opportunity for Jazz's breast cancer drug Ziihera

** Brokerage expects peak annual revenue of $240 million for brain tumor drug dordaviprone, Jazz's newly acquired drug from its buyout of Chimerix CMRX.O

** Six brokerages rate the stock "buy" or equivalent, one "neutral"; their median PT is $187.47, according to data compiled by LSEG

** JAZZ has risen 16.4% in the past 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))